It is a very aggressive tumor, characterized by MYC rearrangement with immunoglobulin genes and mutations in Transcription Factor 3 (TCF3) or its negative regulator Inhibitor of Protein Binding 3 (ID3), as well as coding mutations that affect the B-cell receptor (BCR), G Protein-coupled receptor (GPCR) and Phosphatidylinositol 3-Kinase (PI3K) signaling pathways[4]. Here, TCF3 is linked to neoplasm.